NANO MRNA Company Description

NANO MRNA Co.,Ltd. researches, develops, produces, and sells pharmaceuticals using micellar nanoparticles technology in Japan.

The company’s pipeline products include RUNX1 (mRNA) for the treatment in the area of tissue generation and vaccines; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer.

Its product pipeline also comprises TUG1 (ASO) for glioblastoma multiforme. In addition, it offers Complex, an antibacterial ear drops; cosmetic raw material, and platelet-rich therapy.

The company was formerly known as NanoCarrier Co., Ltd. and changed its name to NANO MRNA Co.,Ltd. in June 2023.

NANO MRNA Co.,Ltd. was incorporated in 1996 and is headquartered in Tokyo, Japan.

NANO MRNA Co.,Ltd.

Country	Japan
Founded	1996
Industry	Biotechnology
Sector	Healthcare
Employees	20
CEO	Shiro Akinaga

Contact Details

Address: Atago Green Hills MORI Tower Tokyo Japan
Phone	81 3 6432 4791
Website	nanomrna.co.jp

Stock Details

Ticker Symbol	4571
Exchange	Tokyo Stock Exchange
Fiscal Year	April - March
Reporting Currency	JPY
ISIN Number	JP3651120002
SIC Code	2836

Key Executives

Name	Position
Shiro Akinaga	Chief Executive Officer
Koji Fujimoto	Chief Financial Officer